Assay to monitor bladder Cancer recurrence gets FDA nod

Downers Grove, IL-Vysis, Inc. has received FDA approval to market itsUroVysion assay for monitoring bladder cancer recurrence.

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria